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ABSTRACT It has been shown previously in the severe acute respiratory syndrome
coronavirus (SARS-CoV) that two point mutations, N15A and V25F, in the transmem-
brane domain (TMD) of the envelope (E) protein abolished channel activity and led
to in vivo attenuation. Pathogenicity was recovered in mutants that also regained E
protein channel activity. In particular, V25F was rapidly compensated by changes at
multiple V25F-facing TMD residues located on a neighboring monomer, consistent
with a recovery of oligomerization. Here, we show using infected cells that the same
mutations, T16A and A26F, in the gamma-CoV infectious bronchitis virus (IBV) lead
to, in principle, similar results. However, IBV E A26F did not abolish oligomer forma-
tion and was compensated by mutations at N- and C-terminal extramembrane do-
mains (EMDs). The C-terminal EMD mutations clustered along an insertion sequence
speciﬁc to gamma-CoVs. Nuclear magnetic resonance data are consistent with the
presence of only one TMD in IBV E, suggesting that recovery of channel activity and
ﬁtness in these IBV E revertant mutants is through an allosteric interaction between
EMDs and TMD. The present results are important for the development of IBV live
attenuated vaccines when channel-inactivating mutations are introduced in the E
protein.
IMPORTANCE The ion channel activity of SARS-CoV E protein is a determinant of
virulence, and abolishment of channel activity leads to viral attenuation. E deletion
may be a strategy for generating live attenuated vaccines but can trigger undesir-
able compensatory mechanisms through modiﬁcations of other viral proteins to re-
gain virulence. Therefore, a more suitable approach may be to introduce small but
critical attenuating mutations. For this, the stability of attenuating mutations should
be examined to understand the mechanisms of reversion. Here, we show that
channel-inactivating mutations of the avian infectious bronchitis virus E protein in-
troduced in a recombinant virus system are deﬁcient in viral release and ﬁtness and
that revertant mutations also restored channel activity. Unexpectedly, most of the
revertant mutations appeared at extramembrane domains, particularly along an in-
sertion speciﬁc for gammacoronaviruses. Our structural data propose a single trans-
membrane domain in IBV E, suggesting an allosteric interaction between extramem-
brane and transmembrane domains.
KEYWORDS coronavirus, infectious bronchitis virus, envelope protein, channel
activity, NMR structure, small membrane protein
The avian infectious bronchitis virus (IBV) is a coronavirus (CoV) ﬁrst isolated in 1937(1) that can seriously devastate and cause severe economic losses to the poultry
industry worldwide (2). IBV is highly contagious and causes pathology ranging from
mild respiratory symptoms to severe kidney and oviduct diseases, which translates into
poor weight gain, renal disease, and decreased egg production and quality. It has been
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estimated that IBV infection in a commercial ﬂock with the best possible management
practice reduces income by approximately 3% (3).
CoVs are single-stranded positive-sense enveloped RNA viruses that belong to the
subfamily Coronavirinae in the family Coronaviridae and are organized into four genera
(4–6), namely, alpha-, beta-, gamma-, and delta-CoV. In humans, CoVs cause approxi-
mately 30% of common colds, whereas the severe acute respiratory syndrome coro-
navirus (SARS-CoV) and the recently emerged Middle East respiratory syndrome coro-
navirus (MERS-CoV) have produced near pandemics (7, 8).
No effective licensed treatments exist against coronavirus infections (9–11), but live
attenuated vaccines (LAVs) (12–16) and fusion inhibitors (17) are promising strategies.
Nevertheless, the chances of reappearance of virulent phenotypes, drug side effects,
and resistance call for continued antiviral development, which depends on an intimate
knowledge of the coronavirus molecular biology (18).
One CoV component critical for pathogenesis is the envelope (E) protein. E proteins
are short polypeptides (76 to 109 amino acids) with at least one transmembrane
domain (TMD) that exist in small amounts in virions but are found abundantly in
internal membranes of infected cells, mostly localized to the endoplasmic reticulum-
Golgi intermediate compartment (ERGIC) (19–24). In animal models, deletion of SARS-
CoV E protein reduced pathogenicity and mortality (25), and a recombinant SARS-CoV
lacking the E gene led to increased apoptosis and downregulation of genes related to
inﬂammation in infected cells, whereas administration of E protein in trans reduced the
stress response (26).
Development of CoV LAVs that are based on modiﬁcations of the E protein requires
an accurate knowledge of critical residues and/or domains, as well as the compensatory
mechanisms available to recover virulence. Deletion of E protein, as shown for SARS-
CoV E, triggers unwanted compensation mechanisms that recover critical protein-
protein interactions. For example, SARS-CoV ΔE passaged in cell culture led to the
appearance of a chimeric membrane (M) gene; the last four amino acids of this chimeric
protein formed PDZ-binding motifs (PBM) (27), shown to be critical for viral pathogen-
esis (28). Similarly, in mouse models, SARS-CoV ΔE led to the appearance of a mutated
variant of 8a protein with an internal PBM which resulted in reversion to virulence (27).
An alternative strategy may be to make small multiple but critical attenuating altera-
tions, in a context where the functional domains of the protein are left almost intact,
so as to improve the overall stability of the attenuated virus for the purpose of vaccine
development.
CoV E proteins form homopentameric ion channels (IC) with poor or no ion
selectivity (29, 30). Mutations at two residues in the predicted TMD of SARS-CoV E, N15A
and V25F (Fig. 1), abolished channel activity in vitro (31). Compared with the wild-type
FIG 1 Sequence alignment of representative CoV E proteins. Amino acid sequence of E proteins from TGEV (transmissible gastroenteritis virus; NCBI accession
no. ABG89336.1) (alpha-CoV), MHV (murine hepatitis virus; AAC36596.1), SARS-CoV (severe acute respiratory syndrome coronavirus; NP_828854.1), Middle-East
respiratory syndrome coronavirus (MERS-CoV; YP_009047209.1) (beta-CoV), and IBV (infectious bronchitis virus; P05139.2) (gamma-CoV). The alignment was
obtained using Clustal O (https://www.ebi.ac.uk/Tools/msa/clustalo/) and shows an “insert” sequence speciﬁc to IBV E. The positions previously mutated in
SARS-CoV E that generated IC-inactive mutants (32) are indicated with vertical arrows, with the ﬁrst arrow pointing to conserved polar residues (red). Numbering
corresponds to the IBV E sequence. Two putative TMDs are indicated, predicted with TMHMM 2.0 (http://www.cbs.dtu.dk/services/TMHMM-2.0/) (71) from
residue 13 to 32 and from residue 47 to 65, although Phobius (http://phobius.sbc.su.se/) (47) predicts one TMD, from residue 12 to 31. The consensus secondary
structure in the region represented by TM2 is predicted to have -structure ﬂanking a disordered coil around the conserved proline (NPS@: Network Protein
Sequence Analysis [72]). In IBV E, this -coil–-region is represented by residues 48 to 68. A similar consensus secondary structure is predicted for E proteins
in other CoVs, except alpha-CoVs (TGEV).
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virus, these mutants displayed similar growth kinetics but reduced ﬁtness in infected
cells (32). However, introduction of these mutations in a recombinant mouse-adapted
SARS-CoV (MA15) resulted in in vivo attenuation, and revertant mutants that regained
viral ﬁtness and pathogenicity also regained channel activity (32).
The TMD of SARS-CoV E has been characterized in lipid membranes (33, 34) and in
dodecylphosphatidylcholine (DPC) micelles (35). Whereas Asn15 is facing the lumen of
the channel, Val25 is close to the helix-helix interface (34, 35), although in another
computational model, it was right at the helix-helix interface (33, 36). Consistent with
the expectation that mutation V25F would disrupt TM-TM interactions, compensatory
mutations clustered along the helix interface opposite Val25 (32).
Most outstanding, however, is that recombinant virus carrying mutation N15A in its
E protein, which enabled mice to survive, did not revert to a more pathogenic
phenotype in vivo (32). Only when multiple passages were performed in cell culture did
the mutation A15D appear (and IC activity was regained). This is surprising because
mutation A15D involves at least one transversion (C↔A), i.e., a conversion between
purine and pyrimidine. Mutations to other polar residues were not selected by the virus
(32) even when only a single transition was required, such as G↔A in A15T. Transitions
are more likely than transversions, as they involve exchanges between two purines or
between two pyrimidines (37).
From an alignment of E sequences representative of CoV groups, the position
represented by Asn15 in SARS-CoV E is always occupied by a polar residue, Thr in
gamma-CoV. IBV E mutation T16A resulted in decreased Golgi complex disruption (38,
39), proposed to facilitate the efﬁcient trafﬁcking of virions (38–42). However, the
effects observed for T16A could not be restored by the conservative polar substitutions
to Ser, Asn, or Gln (39). Since the IC activities of these IBV E mutants were not measured
(32, 39), these effects cannot be unequivocally attributed to loss of IC activity. Never-
theless, these results suggest that CoV E proteins have an exquisite speciﬁcity for the
identity of the polar residue at this position. Similarly, SARS-CoV E Val25 is aligned with
IBV E Ala26, and therefore a similar pattern of revertant mutants would be expected for
IBV E mutation A26F.
The latter hypothesis assumes that IBV E and SARS-CoV E adopt similar structures.
However, although in general CoV E proteins have a cytoplasmic C-terminal domain
and a lumenal N terminus (22, 24, 39, 43), the presence of a single -helical TMD has
been shown only for the E proteins of beta-CoVs SARS-CoV (33–36, 44, 45) and
MERS-CoV (46). It is not known if additional TMDs or embedded motifs exist in other
CoV E proteins. For example, two TMDs (residues 13 to 32 and 47 to 65) are predicted
for IBV E using TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/), but only one
TMD (residues 12 to 31) is predicted using Phobius (http://phobius.sbc.su.se/) (47).
Therefore, in the present study, we have generated recombinant IBVs (rIBV) harbor-
ing the above-mentioned mutations (T16A or A26F) in the E gene (rT16A and rA26F
mutants) to test their effect on genome replication/transcription kinetics, protein
translation, and virus assembly in the context of IBV infection in cells. We have also
analyzed the revertant mutations that appear in the IBV E sequence and correlate their
locations with structural features of IBV E obtained by solution nuclear magnetic
resonance (NMR).
RESULTS
IBV E protein IC activity is not essential for virus replication in cell culture.
Previous studies on SARS-CoV E showed that two residues in the TMD, Asn15 and Val25
(Fig. 1, arrows), are essential for IC activity, viral ﬁtness, and pathogenesis (32). Based on
the CoV E protein alignment, the two equivalent positions in IBV E are Thr16 and Ala26.
Therefore, we hypothesized that similar mutations in IBV E protein, T16A and A26F,
would also disrupt IC activity. To verify this, full-length IBV E proteins carrying each of
these two mutations were expressed and puriﬁed, and channel activity was tested in
black lipid membranes (BLM), i.e., supported lipid bilayers. While the wild-type IBV E
Channel-Inactivating Mutations in IBV E Journal of Virology
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showed channel activity, no conductance could be measured for either of these two
mutants (not shown).
To investigate the impact of the loss of IBV E IC activity in the T16A and A26F
mutants on IBV replication, these mutations were introduced in a recombinant IBV
(rIBV), to obtain rIBV-E-T16A (rT16A mutant) and rIBV-E-A26F (rA26F mutant). These
mutant viruses could be recovered from electroporated Vero cells, and their E gene
sequences were veriﬁed. The effect of these mutations on IBV production was moni-
tored by analysis of plaque size and growth curves in infected Vero cells. Plaques
formed by both IC-inactive mutants were similar in morphology to those caused by
wild-type rIBV (WT-rIBV), although they were slightly smaller for the rA26F mutant (Fig.
2A). The growth kinetics of the two mutants was studied with Vero cells infected at a
multiplicity of infection (MOI) of2, whereby virus titers in both cell lysates and culture
supernatants were determined by plaque assay. In these experiments, after lysis by
three freeze-thaw cycles, virus titers of cells infected by WT-rIBV and rT16A or rA26F
mutants were similar (Fig. 2B); i.e., IBV E IC activity is not essential for virus replication
in cell culture. Consistently, levels of IBV positive-sense subgenomic RNA2, or IBV
structural proteins, were similar for cells infected with WT-rIBV or IBV E mutants (Fig. 2C
and D). However, we note that at a late stage of infection (40 h postinfection [hpi]), the
FIG 2 Growth properties of WT-rIBV and rT16A and rA26F mutant viruses. (A) Comparison of plaque morphologies of WT-rIBV and rT16A and rA26F mutant
viruses. Plaque sizes: 1.00  0.65 mm for WT, 0.88  0.54 mm for rT16A mutant, and 0.59  0.32 mm for rA26F mutant. (B) Vero cells were infected at an MOI
of 2 with WT-rIBV, rT16A mutant, or rA26F mutant, and the viral progeny in total cell lysate was titrated at the indicated times postinfection. (C) Total cellular
RNA was harvested from infected cells at the indicated times postinfection, and IBV positive-sense subgenomic RNA2 (sgRNA2) levels were quantiﬁed by qPCR
and normalized to an internal GAPDH control. (D) Western blot analysis of viral protein expression in Vero cells infected with the WT-rIBV, rT16A mutant, or
rA26F mutant, harvested at the indicated time points. (E) Vero cells were infected as described for panel B, and viral progeny in culture supernatant was titrated.
(F) RNA was extracted from culture supernatant of infected cells, and IBV positive-sense genomic RNA (gRNA) levels were quantiﬁed relative to that of the
wild type at 16 hpi. Error bars represent SEM.
To et al. Journal of Virology
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amount of the cleaved form of IBV S protein was lower in rT16A mutant-infected cells
(not shown), suggesting that the T16A mutation affects S protein trafﬁcking and
maturation.
IBV E protein IC activity is required for the efﬁcient release of infectious
virions. In contrast to the cell lysate results, the titers of the two mutants at 16, 24, and
32 hpi in the culture supernatant were 1 log lower than those corresponding to the WT
virus at the same time points (Fig. 2E). Two explanations may account for this obser-
vation: (i) the IC-inactive mutant viruses might be less efﬁcient in releasing mature
virions, and (ii) the released mature virions might be less infectious. Thus, the culture
supernatant was tested for levels of IBV positive-sense genomic RNA and IBV structural
proteins. While S, M, and N proteins were detected in the supernatant of cells infected
with the wild-type IBV at 24 hpi, no expression could be detected in cells infected with
the mutants (Fig. 2D). Consistently, IBV positive-sense genomic RNA was present at
signiﬁcantly lower levels in the supernatants of cells infected with the rT16A and rA26F
mutants compared to WT-rIBV-infected cells (Fig. 2F). These results show that these
mutations affect the efﬁcient release of mature virions from infected cells. Since both
mutants are IC inactive, this suggests that IBV E protein IC activity may play a crucial
role in viral release.
IBV E IC activity improves viral ﬁtness and virion release. To investigate the
effect of these mutations on viral ﬁtness, competition assays were performed between
the WT and mutants. Vero cells were coinfected with each mutant and WT at a 9:1 ratio.
After 24 h, the resulting virus population was serially passaged, either with only the
culture supernatant (supernatant passage) or with the total cell lysate (total cell lysate
passage). Analysis of the viral population in the culture supernatant of infected Vero
cells showed that WT-rIBV rapidly overtook each of the two IBV E mutants at the ﬁrst
passage, while at the same time the quantities of both mutants decreased (Fig. 3A).
When the viral population in the total cell lysate was studied, the substitution took
place at a lower rate, but it was also apparent. The rT16A mutant still remained
dominant in the population after four passages, but the tendency showed a steady
decline in favor of the WT virus (Fig. 3B). In the case of the rA26F mutant, the WT virus
outcompeted the mutant after only two passages. These results and those in Fig. 2A
FIG 3 Contribution of IBV E IC activity to viral ﬁtness and virion release. Competition assays between the
WT-rIBV (WT; closed circles) and rT16A or rA26F mutant viruses (open circles) were performed in Vero
cells coinfected at a wild type/mutant ratio of 1:9. Either the culture supernatant (A) or whole-cell lysates
(B) were serially passaged every 24 h four times. The quantiﬁcation of the relative abundance of each
virus was performed by sequencing the IBV E gene within the viral progeny.
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show that the A26F mutant is more seriously challenged than the T16A mutant. A
similar set of competition assays was performed in DF-1 cells, where WT-rIBV outcom-
peted both IBV mutants in a similar fashion (not shown). These results show that the
two mutant viruses were challenged in ﬁtness and release. In both aspects, the WT virus
outcompeted the mutants.
rIBV E IC-inactive mutants evolve revertant E mutations. If the effects induced by
these mutations are due to the loss of IC activity, serial passage of mutant viruses in cell
culture should enable the appearance of compensatory mutations in E protein with
recovered IC activity. Thus, WT and mutant viruses were serially passaged 25 times in
Vero or DF-1 cells every 24 h, and the E gene was sequenced at passages 0 (P0), 5, 10,
15, 20, and 25 (P25). In Vero cells infected with WT-rIBV, the E gene was stable
throughout the passages (not shown). However, in cells infected with the rT16A
mutant, the E gene acquired mutation A26V after only 5 passages in both types of cells,
but this mutation remained only in Vero cells (Fig. 4A, left).
It is noticeable that although the conversion to the native residue (from Ala to Thr)
requires only a single nucleotide change, i.e., a transition (G↔A), Ala in T16A did not
revert to Thr in Vero cells even after 25 passages. However, reversion to the original
Thr16 residue took place early in DF-1 chicken ﬁbroblast cells (Fig. 4A, right), from P5.
The fact that A26V appeared in both Vero and DF-1 cells infected with the rT16A
mutant suggests that its acquisition is advantageous for the virus. These results suggest
that although the IBV used is adapted to Vero cells, there is not enough pressure to
change Thr16 if IBV E has IC activity. However, when this residue is mutated and IC
activity is abolished, solutions other than reverting to Thr16 are preferred. In contrast,
chickens are the natural hosts of IBV, and DF-1 cells may provide a more biologically
relevant selective pressure to regain the native Thr16.
FIG 4 Mutations acquired by IC-inactive mutants after serial passages. Vero and DF-1 cells were infected
with the rT16A (A) or rA26F (B) mutant. The mutations observed are indicated in passages P5 to P25,
where underlined mutations dominate in population over the wild-type residue at the corresponding
positions. Regions of IBV E are indicated by color codes: TMD, green; predicted -structure, red; ﬂanking
conserved Pro55, yellow circle; inserted sequence, pink (see Fig. 1); and remaining EMD, blue.
To et al. Journal of Virology
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In contrast to the rT16A mutant, the rA26F mutant produced revertants with
mutations at extramembrane domains (EMDs) (Fig. 4B). In Vero cells (Fig. 4B, left), the
E gene rapidly acquired mutations K58N and F62S in the insert sequence (Fig. 1). In
subsequent passages, the insert only contained mutation Y64H, complemented with
N11D at the N terminus and F26C in the TMD. When passaging was performed in DF-1
cells, only mutations K58N, which appeared only transiently in Vero cells, and N11D,
were observed (Fig. 4B, right).
Defective virion release caused by IC-inactive mutants can be rescued by WT or
revertant IBV E introduced in trans. It may be possible that the rescue of viral ﬁtness
is due to acquired mutations outside the E gene during serial passage of the recom-
binant IC-inactive IBV. To rule out this possibility, E proteins (WT or a T16A/A26V
revertant mutant) were introduced in trans to DF-1 cells infected with the rT16A
mutant.
In the ﬁrst case, cells were ﬁrst transfected with the vector pXJ40 or pXJ40-IBVE,
followed by infection with WT-rIBV at an MOI of 0.05. When cells were transfected
with pXJ40-IBVE, a signiﬁcantly higher level of IBV E was observed than with the pXJ40
vector-transfected cells (Fig. 5A). Similar levels of IBV S and N proteins were detected
in the lysates of WT-rIBV-infected cells with or without transfected IBV E, demonstrating
that overexpression of IBV E has no effect on the replication of IBV structural proteins
in infected cells. In contrast, when cells were infected with the rT16A mutant and
transfected with pXJ40-IBVE, signiﬁcantly higher levels of IBV S and N were observed.
Consistently, a roughly 3-fold increase in the supernatant IBV titers was observed in this
sample compared to that transfected with the pXJ40 vector control alone (Fig. 5B).
Cells infected with the rT16A mutant and transfected with the pXJ40-IBVE-T16A/
A26V revertant mutant also enhanced levels of IBV S and N protein signiﬁcantly
compared to infected cells transfected with pXJ40-IBVE-T16A alone (Fig. 5A). This is
consistent with the higher titers of IBV in culture supernatant after addition of IBVE-
FIG 5 Phenotype recovery of the rT16A mutant after addition of IC-active IBV E (WT or T16A/A26V) in trans. DF-1 cells were transfected
with the plasmids indicated for 24 h, followed by infection with the rT16A mutant for 24 h. (A) Western blot analysis of whole-cell lysates,
with WT-rIBV-infected cells as a control. (B) IBV titer in culture supernatants of rT16A mutant-infected cells determined by plaque assay.
The values are relative to the ﬁrst column (relative IBV titer  1), found in cells transfected with control vector pXJ40. Error bars represent
standard deviations (n  3). (C) Cytopathic effects (CPE) observed under the conditions indicated.
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T16A/A26V in trans. While the transfection of pXJ40-IBVE-T16A failed to recover the
cytopathic effect (CPE) of rT16A mutant-infected cells, transfection with pXJ40-IBVE-
T16A/A26V resulted in a CPE comparable to that caused by transfection with wild-type
IBV E (pXJ40-IBVE) (Fig. 5C). Overall, these experiments demonstrate that the T16A/
A26V revertant introduced in trans can be used to recover lost ﬁtness in the rT16A virus
and that the compensatory mutation A26V made in the E gene of the recombinant IBV
was sufﬁcient for this purpose.
Effect of mutations on E protein IC activity. To test if the observed revertant
mutations restored the IC activity of the E protein, IBV E proteins carrying these
mutations were expressed and puriﬁed and studied in a black lipid membrane setup.
In most cases, the IC activities of the observed revertant mutants were comparable to
that of the WT (Fig. 6). However, in the case of the A26F/K58N and A26F/N11D revertant
mutants, the protein appeared to be more difﬁcult to insert in the bilayer. For the
A26F/N11D mutant, 4 to 5 times more protein was required to observe a signal. Even
then, deﬁned currents were not observed for this mutant; only events of 300 pS or
more, which may represent unstable structures or very large pores with conductances
FIG 6 IBV E IC conductance measurements. (A) Histograms corresponding to the intensities detected for puriﬁed IBV E protein and mutants incorporated in
black lipid membranes (BLM) in 500 mM KCl at pH 6. The membranes contained DOPC:DOPS:DOPE at a 3:1:1 molar ratio. T16A, L25F, A26F, L26F, T16D, and
T16N mutants were IC inactive (not shown). (B) Conductance (in pS) of the samples shown in panel A. We note that IBV-E shows similarities with other viroporins
regarding lipid involvement in pore formation. This might explain the width of the histogram plots and the fact that some mutants do permeabilize the
membrane but that “channels” are short-lived, presumably because of a less efﬁcient stabilization of peptide -helices by lipids. Highly noisy current traces
would be consistent with this view of poor lipid-peptide stabilization that leads to dispersion in conductance values.
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around 4 to 6 nS (not shown). For the A26F/K58N revertant mutant, conductance was
about half of that of the other revertant mutants. In this case, deﬁned channels
appeared but not frequently, which resulted in a larger error in the measured conduc-
tance. The A26F/N11D/K58N triple mutant was better behaved and showed IC activity
but with a different pattern with respect to the WT. The histogram shows that there are
IC events which differ considerably in conductance: a clear peak at 800 pS, another
small, less deﬁned, peak at 100 pS, and also IC events with a broad range of
conductances between them. The 100-pS events lasted for tens of seconds, whereas
the 800-pS events lasted typically only hundreds of milliseconds. Overall, these results
clearly suggest that the two compensatory mutations, N11D and K58N, must be present
in the same protein to regain IC activity.
To test if other polar residues are able to recover IC activity when substituting for the
native IBV E Thr16, two additional E mutants, the T16N and T16D mutants, were also
tested for IC activity. Asn is the equivalent polar residue present in the alignment for
SARS-CoV E protein (Fig. 1), whereas Asp was acquired by the recombinant rSARS-CoV-
E-N15A and regained IC activity (32). Neither of these mutants displayed IC activity (not
shown), supporting the hypothesis that the identity of the polar residue at this position
16 is speciﬁc for each CoV E protein.
Effect of mutations on E protein oligomerization. Because of its predicted
interhelical orientation, the A26F mutation is expected to disrupt E channel oligomer-
ization. However, the above results show that most revertant mutations for the rA26F
mutant, except F26C in Vero cells, appeared in EMDs (Fig. 4). This is clearly in contrast
with a similar SARS-CoV E mutant, the V25F mutant, which acquired several mutations
that clustered along the helix interface opposite Val25 (32). Thus, we tested the effect
of these mutations on IBV E oligomerization, using blue-native polyacrylamide gel
electrophoresis (BN-PAGE) gels.
Quite unexpectedly, mutation T16A disrupted oligomer formation in BN-PAGE gels
(Fig. 7A), and this was also the case for the T16N and T16D mutants, which clearly
explains the lack of IC activity in these mutants. Consistently, the IC-active revertant
mutant for rT16A, the T16A/A26V mutant, regained the ability to form oligomers. In the
same gel, the A26F mutant and its revertant mutants in Vero cells, the A26C, A26F/
FIG 7 Oligomerization of IBV E and its mutants. Results of BN-PAGE electrophoresis of IBV E WT and mutants are shown. (A) Mutants observed in Vero cells;
white arrowheads point to pentamers (upper, dotted box) and monomers (lower); (B) mutants observed in DF-1 cells and L25F and L27F mutants. Gels were
run after the sample was solubilized in 20 mM LMPG detergent. Black arrows indicate pentamers and monomers, as in panel A. The same molecular weight
markers (M) are used in both panels.
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Y64H, and A26C/Y64H mutants, retained the ability to form oligomers. This suggests
that in this case, the cause of IC inactivation is not the disruption of the IBV E oligomers.
The A26F revertant mutants observed in DF-1 cells, the A26F/N11D and A26F/K58N
mutants, also preserved a WT-like oligomer (Fig. 7B).
One possible explanation for the preservation of the oligomeric form in the A26F
mutant is that A26F in IBV E is not at an interfacial position. However, we also tested
the contiguous L25F and L27F mutants, showing that these also preserve native-like
oligomerization (Fig. 7B). When tested for IC activity, these two mutants displayed a
pattern of behavior similar to that of the A26F mutant, with occasional but very noisy
and unstable currents that cannot be ascribed to bona ﬁde ion channels (not shown).
Since at least one of these three residues should have an interfacial orientation, it seems
likely that insertion of a Phe residue at this interfacial position does not disrupt the IBV
E oligomer.
Overall, IC activity and oligomerization results indicate that T16A revertant mutants
tend to restabilize the oligomer and at the same time recover IC function. In contrast, the
effect of A26F revertant mutants appears to reverse an A26F-induced IC-inactivating
conformational change in the IBV E oligomer. Since most of these compensatory
mutations appear only at EMDs, this conformational change may be effective either
through direct physical contact between the central region of the TMD and EMDs or
indirectly through some allosteric mechanism. These alternatives highlight the possi-
bility of a second TMD, as predicted by some algorithms (Fig. 1, TM2), or an embedded
hairpin encompassing this region, which is predicted as being more hydrophobic.
Unfortunately, no structural data are currently available for IBV E. To test if EMD
residues Lys58 and Tyr64 can affect IC activity, they were mutated to Ala and the IBV
E mutants were expressed and puriﬁed before being tested for IC activity. While the
K58A mutant produced few stable IC events, the Y64A mutant produced many IC
events that were stable, between 100 to 500 pS. Therefore, a mutation at K58 affects IC
activity, whereas Y64A has only a minor effect on IC activity. This is consistent with the
way in which revertant mutations appeared: mutation Y64H was present only when
mutation F26C appeared, which is already active by itself (although A26F/Y64H seems
to have IC activity as well [Fig. 6]). In contrast, K58N produced an active channel even
when A26F was still present (Fig. 4B).
Secondary structure of IBV E in SDS and LMPG micelles. Since most of the
compensatory mutations acquired by the rA26F mutant appeared in predicted EMDs of
IBV E, we tested the possibility that IBV E has more than one TMD or an unexpected
topology. Isotopically labeled IBV E was puriﬁed (Fig. 8) and reconstituted in detergent
micelles for NMR studies. Several detergent systems were tested, and most of them
failed to produce acceptable spectra (not shown). Only sodium dodecyl sulfate (SDS)
and lyso-myristoylphosphatidylglycerol (LMPG) produced spectra of reasonable quality
for structural studies.
Backbone resonance assignment could be achieved for most of the protein. How-
ever, despite the use of a perdeuterated sample, resonances corresponding to 10
residues in the predicted C-terminal EMD were not observed, even in the presence of
SDS. To determine whether oligomerization of E protein was responsible for the
missing residues, E protein was titrated with increasing SDS and/or diluted. Oligomer-
ization was monitored using BN-PAGE gels. However, even under conditions in which
IBV E was 100% monomeric, the spectral quality did not improve (data not shown),
suggesting that the region with missing resonances is exposed to an intermediate
exchange between two or more conformations.
The secondary structure of IBV E in both SDS and LMPG micelles was predicted
based on the chemical shifts by using TALOS and showed mostly a succession of
-helical and coil stretches (Fig. 9). In SDS, there are ﬁve -helical stretches, H1 to H5
(Fig. 9A). The N-terminal region down to Ala45 appears almost entirely -helical but is
seemingly interrupted at Gly12 and Ala41. These residues delimit the only TM -helix
(H2), ﬂanked by short -helices N- and C-terminally (H1 and H3, respectively). At the
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C-terminal end, two additional short -helices span Gly56 to Gly69 (H4) and Pro75 to
Glu84 (H5), respectively. Since some residues within these stretches are resistant to
hydrogen-deuterium (H/D) exchange (see below), H4 and H5 are probably bound to the
SDS micelle surface. In LMPG (Fig. 9B), the N-terminal -helical stretch formed by H1 to
FIG 8 Full-length IBV E protein construct. (A) Amino acid sequence of full-length IBV E construct used in this paper, numbered to exclude the His tag (from
residues 23 to 0 [in gray]). The two mutations, C44A and C45A, are indicated. (B and C) SDS-PAGE (B) and MALDI-TOF MS spectra (C) of the HPLC-puriﬁed
E protein. Expected molecular size is 14,978 Da.
FIG 9 Secondary structure of IBV E. The predicted secondary structure (color coded) of IBV E according
to standard prediction tools (72) is shown at the top of the ﬁgure. (A and B) TALOS chemical shift-based
predictions of secondary structure in SDS (A) and LMPG (B), with consensus indicated underneath each
vertical bar (H, helix; E, sheet; L, loop). Each vertical bar shows a color-coded distribution of probabilities
for the different secondary-structure types.
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H3 extends until Thr50. This is followed by a helical stretch analogous to H4 in SDS but
slightly shorter, from Gly56 to Thr67. H5 is not observed in LMPG and may be unfolded
or may partially adopt -structure.
Consistent with the data obtained with detergents, IBV E incorporated in DMPC lipid
bilayers (Fig. 10) has an amide I band centered at 1,657 cm1, typical of -helix. This
shows that the secondary structure of IBV E in lipid bilayers is predominantly -helical,
although the contribution of random coil is possible but difﬁcult to evaluate. Addition-
ally, a small but clear shoulder represents -structure, at 1,634 cm1. This -structure
may correspond to the predicted -structure regions in IBV E around Pro55 (Fig. 9, top)
and may be favored in a lipidic environment.
Membrane-embedded regions of IBV E in SDS and DMPC lipid bilayers. Al-
though LMPG produced good NMR spectra, in this detergent only 4 to 5 resonances
were found to be resistant to H/D exchange in a 1H-15N TROSY-HSQC (transverse
relaxation optimized spectroscopy-heteronuclear single quantum coherence spectros-
copy) experiment (not shown). However, in SDS, 26 residues in the ﬁrst predicted TMD
region were found to be resistant to exchange, from Asn11 to Ala36 (Fig. 11A). This
represents a single TMD, although slightly longer than the predicted one (Fig. 1, TM1).
Other parts of IBV E are also partially protected from H/D exchange, e.g., juxtamem-
brane residues Ala41 and Ala44, as well as residues in the C-terminal EMD, e.g., Tyr66,
Gly69, Asn73, Leu77, and Ile81 (Fig. 11B). This last region may correspond to an -helix
tightly bound to the detergent surface. Overall, the H/D exchange data obtained in SDS
is not compatible with the presence of a second TMD or membrane-embedded hairpin
in the C-terminal EMD. Under these conditions, physical contact between Ala26 and the
“insert” sequence K58GTAFV seems unlikely.
However, incorporation of IBV E in DMPC lipid bilayers shows that after exposure to
D2O, only 20 to 30% of the amide II band is reduced (Fig. 10). This represents between
76 and 87 residues protected from exchange and, in principle, is compatible with a
second TMD or an embedded hairpin in the C-terminal EMD.
DISCUSSION
Effect on virion release. Our results show that the rIBV E IC-inactive T16A and A26F
mutants display kinetics in genome replication/transcription, protein translation, and
virus assembly inside the infected cells similar to those of the wild-type virus but lead
to a reduction in the release of infectious virions. It is known that CoV virions appear
FIG 10 Infrared spectra of IBV E incorporated in DMPC lipid bilayers. Nonpolarized infrared spectra of the
amide I and II regions in H2O at low hydration (solid line) or hydrated in D2O (broken line) are shown.
The amide II is indicated by a star. Arrowheads indicate the maxima in the amide I band. The small
reduction in amide II intensity after D2O exposure is due to N-H to N-D conversion.
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in large vacuoles derived from Golgi complex/ERGIC membranes (41) and that CoV
infections are characterized by rearrangements of host cell membranes (40); these
alterations and efﬁcient trafﬁcking of virions are facilitated by IBV E (38–42). Thus, the
reduced virion release for these IC-inactive mutants suggests a role for E protein IC
activity in efﬁcient shedding of mature virions. Previous reports have shown that
substitution of a nonoligomerizing TMD for the IBV E TMD led to the intracellular
accumulation of viral particles (38), highlighting the importance of the IBV E TMD for
the forward trafﬁcking of cargo to the plasma membrane through the Golgi complex.
Incidentally, our preliminary studies suggest that the mutations introduced here also
resulted in differential activation of cellular response pathways, such as alterations in
the induction of apoptotic cell death and production of proinﬂammatory cytokines (not
shown).
Here, we have shown that, as with SARS-CoV (32), IBV E revertant mutants bearing
the T16A and A26F mutations restored both IC activity and viral ﬁtness. However, the
patterns of revertant mutations observed in the two cases are very different.
IBV E A26F mutation. At variance with the results obtained for the SARS-CoV E
V25F mutation, most compensatory changes elicited by IBV E A26F were not located at
the TMD but at the N-terminal (N11D) or C-terminal (K58N, F62S, and Y64H) EMDs. In
the C-terminal EMDs, the changes clustered to an insert region unique to gamma-CoV,
K58GTAFV (Fig. 1). This is surprising, since mutation A26F, like SARS E V25F, is expected
FIG 11 H/D exchange of IBV E in SDS. (A) 1H-15N TROSY-HSQC spectrum of IBV E in SDS, in the presence of 99%
D2O, with H/D exchange-resistant cross-peaks indicated; (B) protection from H/D exchange expressed as a volume
ratio of D2O/H2O peaks (open squares). Residues that cannot be measured due to overlap are excluded (ﬁlled
circles). Peak volumes in H2O are plotted in a logarithmic scale (ﬁlled squares), i.e., larger volumes produce more
reliable values.
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to disrupt TM-TM interactions. However, neither A26F, L25F, nor L27F was particularly
disrupting to IBV E oligomerization in BN-PAGE gels. The interpretation that A26F is not
monomeric is further reinforced by the revertant mutants obtained herein, since
changes occur mostly in EMD regions. Therefore, these results suggest that the
observed revertant mutations do not act to recover oligomerization but to adjust the
existing oligomer conformation. It is also possible that apart from its effect on IC
activity, the A26F mutation may have had other unidentiﬁed adverse effects on IBV
during the course of infection.
The rA26F compensatory mutations observed differed slightly depending on the cell
type used for the passage. For example, although most compensatory mutations
clustered along the unique insert sequence of the IBV E protein, mutation Y64H
appeared only when the virus was passaged in Vero cells. However, these small
differences may not be reproducible. It also remains to be tested whether these
compensatory mutations, especially those found in Vero cells, can lead to a recovery of
native phenotype when introduced in the chicken embryo system.
We hypothesize that the differences observed in SARS-CoV and IBV E revertant
mutants are related to the presence of the insert in the C-terminal EMD of IBV E. It is
possible that Ala26 and residues in the insert that appeared to be mutated in response
to A26F, i.e., K58N, F62S, and Y64H, are in physical contact through a second TMD or
an embedded hairpin in the C-terminal EMD. Although only one TMD was observed in
SDS micelles, H/D exchange protection in DMPC membranes is as high as 70 to 80%.
Therefore, since cellular membranes are the native environment for IBV E, it is likely that
most of the protein is embedded in, or tightly bound to, the membrane.
Although the present data cannot exclude the possibility of a second TMD in cellular
membranes, this is unlikely because SARS-CoV E and MERS E have similar high per-
centages (70%) of H/D exchange-protected residues when analyzed by infrared (IR)
spectroscopy in model lipid bilayers, yet SARS-CoV E has a NexoCcyto topology (24)
consistent with a single TMD, and both SARS-CoV E and MERS E have a single predicted
TMD conﬁrmed by H/D exchange experiments in detergent micelles (45, 46). Likewise,
there is an overwhelming evidence of a NexoCcyto topology for IBV E (39, 43, 48), which
implies the presence of only one TMD.
The possibility that the membrane environment, but not SDS micelles, facilitates
formation of an embedded hairpin or loop, or more tightly bound -helices, seems
more likely. This would allow direct regulation of the TMD through modiﬁcations in the
insert region of IBV E. Alternatively, these changes may just affect monomer-monomer
and/or monomer-membrane interactions at the EMD through helices H1 (N11D) and H4
(Fig. 1, insert region) and allosterically alter the TMD, reinstating in the oligomer some
lost ﬂexibility that is necessary for IC activity.
IBV E T16A mutation. Similarly to the N15A mutation in SARS-CoV E (32), in the
present work, the IBV E mutation T16A did not mutate to other polar residues at this
position. It can be argued that this is because mutation of Ala16 to polar residues other
than Thr would involve at least two nucleotide changes in the codon. However, neither
of the possible E protein mutants we tested, i.e., the T16D or T16N mutant, recovered
the oligomeric form in BN-PAGE gels or IC activity. This again supports that this polar
residue is speciﬁc for each CoV E sequence. This could be related to their different
effects on E protein oligomerization: in SARS-CoV E, the N15A mutant formed more
stable oligomers than the V25F mutant (49), while in contrast, in IBV E, the T16A mutant
destabilized the oligomer, while its revertant mutants recovered both the ability to
oligomerize and the IC activity. Also, we found that the T16A mutant and those with
similar polar residues at that position are monomeric but that T16A revertant mutants
also recover the ability to oligomerize.
A recent study based on the analysis of IBV E in transfected cells reaches opposite
conclusions regarding the oligomeric state of the T16A and A26F mutants (50). The
latter study analyzed nonquantitatively the relative sedimentation of IBV E in a sucrose
gradient after extraction from transfected cells with the detergent DDM (n-dodecyl--
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D-maltoside). In these experiments, WT IBV E appeared in two fractions assigned to low
(monomeric)- and high (oligomeric)-molecular-weight pools at an approximately 40:60
ratio. When cells were transfected with the A26F and T16A mutants, only one fraction
appeared: low (A26F) or high (T16A). Consistent with previous results (38, 39), the same
paper (50) showed that T16A, but not A26F, prevented Golgi complex disassembly and
reduced the trafﬁcking of vesicular stomatitis virus (VSV) G but greatly enhanced
virus-like particle (VLP) production. The authors associated the effects on Golgi com-
partment disassembly and trafﬁcking with an IBV E monomeric form present in both
the WT and the A26F mutant. VLP production may be related to an oligomeric form
(more stable in the T16A mutant), although in previous experiments by the same
group, VLP formation did not differ between the WT and the T16A mutant (38, 39).
However, we note that when infected cells were used (50), almost all (95%) of WT IBV
E appeared in the high-molecular-weight band. It would be interesting to obtain the
above results in infected cells.
While our data are in agreement with the notion that disruptive effects on the
secretory pathway and VLP formation and assembly are not related to IC activity, the
role of the monomeric and oligomeric forms of IBV E is precisely the opposite:
disruption of the secretory pathway is associated with an oligomeric form (WT and
A26F mutant), whereas a monomeric form (T16A mutant) enhances VLP formation.
Structural model of IBV E and nonobserved resonances. Despite the prediction
of short stretches of -structure in C-terminal tails of CoV E proteins, no obvious
-structure was detected for IBV E in SDS or LMPG micelles. Instead, the structure
appears to be formed by several -helical stretches, reminiscent of other viroporins
(51–53). Residues Val63 to Lys65 were not observable in SDS, but considering that
residues immediately ﬂanking this stretch are -helical, the remaining three residues
are likely to be part of an -helix in H4. This is supported by the -helical conformation
of H4 that could be observed in its entirety in LMPG.
We have suggested previously that the region near the conserved Pro residue in
CoV E proteins (Pro55 in IBV E) has a high abundance of -branched and bulky residues
that can potentially destabilize -helical conformation (45), and this region is predicted
to have -structure (Fig. 9). SARS-CoV E in lipid bilayers has an infrared amide I
signature that corresponds to a mostly -helical protein (45). However, its synthetic
fragment 46-60 adopts 100% -structure (44, 51), and peptides inspired on that domain
form amyloid ﬁbers (51, 54), whereas peptide 50-65 forms 100% -helix (unpublished
result). That the region around the conserved Pro55 has structural ﬂexibility is sup-
ported by the fact that mutations designed to increase its -helical propensity pro-
duced an IR spectrum with slightly less -structure and more -structure (45). Similarly
to SARS-CoV E, we have shown that the IR spectrum of IBV E in lipid bilayers is mostly
-helical but shows a minor contribution of -structure.
For IBV E in detergent, short stretches before and after the conserved Pro55,
predicted to form -structure, were difﬁcult to detect by NMR, even when using a
perdeuterated sample. For example, the sequence from Trp51 to Ile54 could not be
assigned in SDS or LMPG, and therefore the conformation of this region remains
uncertain. This again points to a conformational exchange that takes place at an
intermediate rate between -helix and -sheet forms. The -helix form would be more
favored in detergent (45), thus broadening the linewidth and preventing the observa-
tion of some cross-peaks in this region.
This dynamic exchange may be related to possible roles of E proteins in inducing
membrane curvature or in the scission of viral particles from cellular membranes (15,
38, 55–58). Compensatory changes that helped regain virulence were observed in the
region around conserved Pro55 after deletion of a C-terminal PDZ-binding motif (PBM)
(28, 59) in SARS-CoV E (27), which seems plausible if the region possesses sufﬁcient
-helical propensity. Truncations in the same region of SARS-CoV E also resulted in
attenuation (60). This has led to the development of SARS-CoV LAVs based on E-deleted
and E-truncated virions (57, 58, 60, 61). Thus, both channel activity and cytoplasmic tail
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integrity (60) are required simultaneously to achieve virulence. The native function of
this region in SARS-CoV E, as well as H4-H5 helices in IBV E, is unknown, but this region
is probably involved in protein-protein interactions.
Vaccines. Based on the locations of the compensatory mutations found in the E
protein of rT16A and rA26F mutants, consistent with the results obtained in SARS-CoV
E, the rT16A mutant seems to have fewer options that lead to a channel-active mutant,
and the mutation even reverted back to the original Thr when serially passaged in DF-1
cells. However, it is possible that the stability of these mutations in ovo or in vivo may
be different from that in vitro.
The results point to compensatory mutations for the rA26F mutant located in an
insert region characteristic of gamma-CoV. Therefore, a strategy for vaccine develop-
ment that prevents back-mutations might be to combine the A26F mutation with
simultaneous mutations or deletions in this insert region. In addition, given the
importance and speciﬁcity of the position occupied by a polar residue, Thr16 in IBV E,
one may replace this residue with another one that requires two or three transversions.
One challenge to overcome in the recovery of LAV produced in vitro, however, is that
these mutations may render the recombinant virus deﬁcient in virion release, as shown
for the rT16A and rA26F mutants, which may compromise the efﬁcient production and
puriﬁcation of the vaccine products.
Overall, the present study establishes the initial basis for such LAV development
targeting the IBV E protein and characterizing hot spots that compensate for loss of
virulence in IC-inactive mutants.
The results obtained herein are especially relevant for the development of live
attenuated IBV vaccines, which, along with inactivated boost vaccines, is one of the
promising ways to control IBV infection. Speciﬁcally, it would be desirable to directly
and rationally engineer mutations with an attenuation of pathogenicity that is difﬁcult
to reverse, while at the same time retaining as much immunogenicity as in the
wild-type virus. Indeed, currently commercial LAVs are produced after multiple pas-
sages of virulent ﬁeld isolates in embryonated domestic fowl eggs. This has several
drawbacks, such as lack of cross-protection due to many different IBV serotypes,
reduced viral immunogenicity, mutations that enable back-mutations that recover
virulence, and persistent high infectivity and virulence for embryos, which prevents
administration in ovo.
MATERIALS AND METHODS
Cells and virus. The African green monkey kidney-derived Vero cells and the DF-1 (ATCC CRL-12203)
chicken ﬁbroblast cells were obtained from the American Type Culture Collection (ATCC). They were
cultured at 37°C in Dulbecco’s modiﬁed Eagle medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), penicillin (100 U/ml), and streptomycin (100 g/ml). The egg-adapted Beaudette strain of
IBV (ATCC VR-22) was obtained from the ATCC and adapted to Vero cells as described previously, i.e., 65
passages on Vero cells (p65) (62). Propagation of IBV was performed in Vero cells in FBS-free DMEM. To
prepare virus stock, the cell lysate obtained 24 hpi was treated with three freeze-thaw cycles, followed
by clariﬁcation at 1,500  g for 30 min at 4°C, and the supernatant was stored at 80°C. The titer of the
virus stock was determined by plaque assays.
Construction of rIBV. Recombinant IBV (rIBV) viruses carrying mutations in the E gene which
abolished the IC activity were constructed. Brieﬂy, ﬁve fragments spanning the entire IBV genome,
fragments A to E, had been previously cloned into pKT0, pCR-XL-TOPO (Invitrogen), or pGEM-T Easy
(Promega) vector, ﬂanked by restriction site BsmBI (fragment A) or BsaI (fragments B, C, D, and E) (63).
The pGEM construct containing the cDNA fragment (fragment E) spanning the genomic region of
nucleotides 20901 to 27608 of IBV, which includes the E gene, was used as the background to introduce
mutations using site-directed mutagenesis. Each E fragment contained different point mutations within
the E gene that would result in amino acid substitutions to abolish IC activity: T16A (ACA to GCA) and
A26F (GCA to TTT). The wild-type fragments A, B, C, and D, as well as the E fragments carrying mutations
in the E gene, were digested from the respective plasmids and gel puriﬁed. The genomic fragments were
assembled by DNA ligation using T4 DNA ligase to generate full-length cDNA clones. In vitro transcription
was performed using the mMessage mMachine T7 kit (Ambion, Austin, TX), according to the manufac-
turer’s instructions. In addition, an N transcript was generated using the IBV N gene and the 3=
untranslated region (UTR) as the templates. The IBV full-length and N transcripts were puriﬁed with
phenol-chloroform before introduction into Vero cells by electroporation. The rIBVs were harvested from
the cell supernatant, and the engineered mutations in the E gene were validated by real-time PCR
(RT-PCR) and DNA sequencing as described below.
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RNA extraction and RT-PCR analysis. Total RNA from cultured cells was extracted with TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions. Brieﬂy, cells were lysed with 1 ml TRIzol
per 10 cm2 effective growth area, and the lysates were mixed with one-ﬁfth volume of chloroform. After
centrifugation at 12,000  g at 4°C for 15 min, the aqueous phase was mixed with an equal volume of
isopropanol. RNA was pelleted by centrifugation at 12,000 g at 4°C for 15 min, washed twice with 70%
ethanol, and reconstituted in RNase-free water. The cDNA was reverse transcribed from total RNA using
the oligo(dT) primer and ImProm-II reverse transcription system (Promega) according to the manufac-
turer’s instructions. Real-time PCR was performed using a SYBR select PCR kit (Life Technologies) in an
Applied Biosystems 7500 real-time PCR system (Applied Biosystems) according to the manufacturer’s
instructions. The following PCR primers (forward and reverse) were used: IBV subgenomic RNA2,
5=-CTATTATACTAGCCTTGCGCTAGA-3= and 5=-AGGTGTTACCAACATCTCTCACC-3=; IBV total RNA, 5=-A
GTAGCTTGGAAACGAACGGT-3= and 5=-CGGCACTGGCATCTTTAGAC-3=; -actin, 5=-TACGCCAACACAGT
GCTGTCT-3= and 5=-TCTGCATCCTGTCGGCAAT-3=.
Virus genome sequencing. The IBV genome region spanning nucleotides 23944 to 24693 that
contains the E gene was sequenced after reverse transcription and PCRs. Brieﬂy, total RNA from infected
cells was extracted as described above. To obtain the cDNA, 5 g of extracted RNA was reverse
transcribed using the oligo(dT) primer. The cDNA product was used as the template for the subsequent
PCR using forward primer 5=-CGCTCCAACAACTAATACAAG-3=, reverse primer 5=-AATGTTAAGGGGCCAA
AAGC-3=, and the Q5 DNA polymerase (New England BioLabs), in accordance with the manufacturer’s
instructions. The PCR product was puriﬁed using the Wizard DNA Clean-Up system (Promega) and
sequenced with primer 5=-TTGAAACTGGTGAGCAAGTGA-3=.
Growth kinetics and plaque assays. Culture supernatants of IBV-infected cells collected at different
time points were clariﬁed by centrifugation, followed by 10-fold serial dilution using serum-free DMEM.
The viral titers were determined by plaque assay. Brieﬂy, diluted supernatants were applied to conﬂuent
monolayers of Vero cells. After 2 h of adsorption, medium was removed and cells were washed twice with
DMEM. Cells were overlaid with DMEM containing 0.4% agarose and incubated at 37°C for 2 days. The
agarose overlay was removed, and cells were ﬁxed with 4% formaldehyde before staining with crystal
violet. Finally, the plaque numbers were counted, and the titers of individual samples were expressed in
the unit of logarithm of PFU per ml. Each sample was titrated in triplicate in each experiment.
Genetic stability through serial passaging of rIBVs lacking IC activity. Conﬂuent monolayers of
Vero or DF-1 cells cultured in 35-mm2 dishes were infected with WT-rIBV, rIBV-E-T16A (rT16A), or
rIBV-E-A26F (rA26F) at an MOI of 2. At 24 hpi, culture supernatants were collected and passaged on fresh
monolayers of cells. The rIBVs were serially passaged 25 times, in which the E gene was sequenced at
passages 0, 5, 10, 15, 20, and 25 as described above.
Virus competition assays. Vero and DF-1 cells were used for competition assays. Cells were
coinfected with WT-rIBV and mutant rIBVs at a ratio of 1:9. The viral population was studied in two ways.
In one set of experiments, culture supernatants were collected at 24 hpi and passaged on a fresh
monolayer of cells. In another set of experiments, cells were washed twice at 24 hpi and subjected to
three freeze-thaw cycles and the cell lysates were used to infect subsequent passages of cells. The viruses
were serially passaged four times in both sets. Total RNA from the coinfected cells was isolated, and the
IBV E gene was sequenced as described above. The relative abundance of the WT-rIBV and mutant rIBVs
was determined as previously described (32).
Plasmids and transfection. The cDNA sequence of IBV E was ampliﬁed by RT-PCR of RNA extracted
from IBV-infected cells by using primers 5=-CGGAATTCCACCATGAATTTATTGAATAAG-3= and 5=-CCGCTC
GAGTCAAGAGTACAATTTGTC-3=. The PCR product was inserted into vector pXJ40 using EcoRI and XhoI
restriction sites. Mutations of the IBV E protein which abolish its IC activity were generated by
site-directed mutagenesis using the following primers: T16A Forward, 5=-CGCTAGAGGAGAATGGAAGTT
TTCTAGCAGCGCTTTACATA-3=, and T16A Reverse, 5=-TATGTAAAGCGCTGCTAGAAAACTTCCATTCTCCTCTA
GCG-3=; A26F Forward, 5=-CAGCGCTTTACATAATTGTAGGATTTTTATTTCTTTATCTTCTAGGTAGAGCACTTC
AAG-3=, and A26F Reverse, 5=-CTTGAAGTGCTCTACCTAGAAGATAAAGAAATAAAAATCCTACAATTATGTAA
AGCGCTG-3=. Transfection was performed using Lipofectamine 2000 reagent (Invitrogen) according to
the manufacturer’s instructions. Brieﬂy, cells were plated in 12-well plates and transfected with 0.8 g of
plasmid DNA. At 24 h posttransfection, cells were infected with IBV at MOI of 0.05 and continued to be
incubated before being harvested for protein and/or RNA for analysis.
Western blot analysis. Harvested cells were centrifuged at 16,000  g for 1 min, and the cell pellets
were lysed in 1 radioimmunoprecipitation assay (RIPA) buffer. Cell lysates were analyzed by Western
blotting using the appropriate antibodies. The antisera against IBV S, E, M, and N proteins were obtained
from rabbits immunized with bacterially expressed fusion proteins as previously described (64, 65).
-Actin acted as a loading control. Bound primary antibodies were detected using anti-mouse or
anti-rabbit IgG antibodies conjugated with horseradish peroxidase (Dako) and with a chemiluminescence
detection kit (Amersham Biosciences) in accordance with the manufacturer’s instructions. All experi-
ments were repeated at least three times, with similar results, and one of the representative results is
shown.
Protein expression and puriﬁcation. Both IC activity and NMR results were obtained using
full-length IBV E with an N-terminal 6His tag, followed by a tobacco etch virus cleavage sequence. The
two native cysteine residues (Cys44 and Cys45) were mutated to alanine in all constructs to improve the
yield and purity of the expressed protein. IBV E forms pentamers in perﬂuoro-octanoic acid (PFO) gels,
whether as native form or as a Cys-less C44A/C45A mutant (44). The IVB E gene was cloned into
pNIC28-Bsa4. Mutations in IBV E were introduced by site-directed mutagenesis. The constructs were
transformed into Escherichia coli strain BL21(DE3) CodonPlus for protein expression. Cells cultured
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overnight at 37°C in LB broth was diluted 1:100 into fresh Terriﬁc Broth medium and allowed to grow
until an optical density at 600 nm (OD600) reached 2. Protein expression was induced by the addition of
0.5 mM isopropyl -D-1-thiogalactopyranoside (IPTG). After an overnight culture at 18°C, cells were
harvested by centrifugation at 7,500  g.
Stable isotope-labeled E protein for NMR was produced by initially growing an E. coli culture in LB
medium at 37°C to an OD600 of 0.7. The cell mass was then transferred to M9 minimal medium at 4 times
the concentration factor as described previously (66). The M9 medium was appropriately supplemented
with [15N]NH4Cl, [13C]glucose/[13CD]glucose, and D2O (Cambridge Isotope Laboratories) to produce 15N-,
15N/13C-, or 15N/13C/D-labeled protein. Protein expression was induced by adding 0.5 mM IPTG. After
further culture at 18°C for 6 h, the cells were harvested by centrifugation at 7,500  g.
Cell pellets were resuspended in lysis buffer containing 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 5 mM
imidazole, 2 mM -mercaptoethanol (-ME), and 10% glycerol, supplemented with 1 mM phenylmeth-
ylsulfonyl ﬂuoride (PMSF) and 0.1% lauryldimethylamine N-oxide (LDAO). Cell lysis was achieved by brief
sonication, followed by passing the cells through a microﬂuidizer (Microﬂuidics, USA) ﬁve times at 10 
103 to 12  103 lb/in2. Insoluble particles were removed by centrifugation at 40,000  g for 30 min at
4°C, and the supernatant was loaded onto a nickel-nitrilotriacetic acid resin (Bio-Rad Proﬁnity IMAC, Ni2
charged) preequilibrated with lysis buffer. After overnight binding at 4°C, the resin was washed with 20
mM Tris-HCl (pH 8.0), 300 mM NaCl, 20 mM imidazole, 2 mM -ME, and 10% glycerol. IBV E protein was
eluted with 20 mM Tris-HCl (pH 8.0), 300 mM NaCl, 250 mM imidazole, 2 mM -ME, 10% glycerol, and
0.1% LDAO. The eluent was precipitated with trichloroacetic acid (TCA), lyophilized, and further puriﬁed
by reversed-phase high-performance liquid chromatography (HPLC) by applying a linear gradient of an
isopropanol-acetonitrile (IPA-ACN) mixture (80:20 [vol/vol] with 0.1% TFA) on a Phenomenex Jupiter C4
column (250 by 10 mm, 300-Å pore size, 5-m particle size). The identity and purity of peptide fractions
were conﬁrmed by SDS-PAGE and in-gel trypsin digestion, followed by matrix-assisted laser desorption
ionization–time of ﬂight tandem mass spectrometry (MALDI-TOF MS-MS).
Conductance measurements. The experiments reported here were carried out in single ion
channels reconstituted on planar membranes. Planar bilayer membranes were formed from two
monolayers prepared from a lipid mixture containing 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), and 1,2-dioleoyl-sn-glycero-3-phospho-
ethanolamine (DOPE) at a 3:1:1 (DOPC:DOPS:DOPE) ratio in pentane on 70- to 90-m-diameter
oriﬁces in the 15-m-thick Teﬂon partition that separates two identical chambers (67, 68). The
oriﬁces were pretreated with a 1% solution of hexadecane in pentane. Aqueous solutions of KCl were
buffered with 5 mM HEPES at pH 6. All measurements were performed at room temperature.
Single-channel insertion was achieved by adding 2 to 3 l of a 150-g/ml solution of protein in the
buffer that contains acetonitrile-isopropanol (40:60) on the cis side of the chamber.
An electric potential was applied using Ag/AgCl electrodes in 2 M KCl–1.5% agarose bridges
assembled within standard 250-ml pipette tips. The potential was deﬁned as positive when it was higher
on the side of the protein addition (the cis side of the membrane chamber), whereas the trans side was
set to ground. An Axopatch 200B ampliﬁer (Molecular Devices, Sunnyvale, CA) in the voltage clamp mode
was used to measure the current and applied potential. The chamber and the head stage were isolated
from external noise sources with a double metal screen (Amuneal Manufacturing Corp., Philadelphia, PA).
The single-channel conductance was obtained from the current measurement at an applied potential of
100 mV in symmetrical salt solutions.
Gel electrophoresis. Blue-native PAGE (BN-PAGE) was performed as described previously (69). Lyoph-
ilized peptide was solubilized at 0.1 mM in sample buffer containing 20 mM lyso-myristoylphos-
phatidylglycerol (LMPG).
NMR spectroscopy. Lyophilized IBV E protein was solubilized at 0.8 mM in 50 mM sodium phosphate
(pH 5.5), 50 mM NaCl, and 200 mM SDS or LMPG. For H/D exchange experiments, solubilized IBV E sample
was relyophilized overnight and resolubilized in D2O. NMR experiments were performed at 313 K with
Avance-II 700 NMR spectrometers with cryogenic probes. Sodium 2,2-dimethyl-2-silapentane-5-sulfonate
(DSS) was used as the internal reference for 1H nuclei. The chemical shifts of 13C and 15N nuclei were
indirectly referenced from the 1H chemical shifts (http://www.bmrb.wisc.edu/ref_info/cshift.html). NMR
data were processed using Bruker TopSpin 3.1 and analyzed using CARA (http://cara.nmr.ch/). Sequence-
speciﬁc assignment of backbone 1HN, 15N, 13C’, 13C, and 13C was achieved by using 2D [1H-15N]-TROSY-
HSQC, 3D HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, and CBCA(CO)NH on a 15N/13C/D-labeled IBV E
protein. Secondary structure was predicted using TALOS (70).
Infrared spectroscopy. IBV E incorporation in DMPC lipid bilayers and collection of ATR-FTIR
(attenuated total reﬂection-Fourier transform infrared) spectra was performed as described previously
(34). Approximately 100 l of sample with a 50:1 lipid/protein molar ratio was applied to a trapezoidal
(50 mm  2 mm  20 mm) Ge internal reﬂection element (IRE). The areas of the amide I (C  O
stretching) and amide II (N-H bending, centered at 1,550 cm1) were obtained by peak integration
from 1,600 to 1,700 cm1 and from 1,510 cm1 to 1,580 cm1. The hydrogen-deuterium (H/D) exchange
was calculated by measuring the relative area of the amide II to amide I band, before and after addition
of D2O, as described previously (34).
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